Imperagen Raises £5 Million to Combine AI and Quantum Physics for Faster Enzyme Engineering

A UK-based biotech startup called Imperagen has raised £5 million (around $6.7 million) in seed funding to improve how enzymes are developed using artificial intelligence and quantum physics.

The funding round was led by PXN Ventures, with additional support from IQ Capital and Northern Gritstone.

Founded in 2021 by researchers from the Manchester Institute of Biotechnology, Imperagen is working on technology that could make enzyme engineering significantly faster, cheaper, and more accurate compared to traditional methods.

Why Enzyme Engineering Matters

Enzymes are important in many industries, especially healthcare and pharmaceuticals.

They are widely used in:

• Drug development
• Food production
• Agriculture
• Biofuel manufacturing
• Sustainable industrial processes

Traditionally, developing new enzymes involves a slow trial-and-error process in laboratories. Scientists often need to test thousands of enzyme variations manually, which takes time and resources.

Imperagen wants to change that using AI-powered simulations.

How Imperagen’s Technology Works

Instead of relying mostly on physical lab experiments, Imperagen uses advanced quantum physics simulations to predict how enzyme mutations may behave before they are tested in real life.

The company says its system can explore millions of possible enzyme variations digitally.

After that, custom AI models analyze the data and identify the most promising enzyme designs. The company also uses robotics and automation to continuously generate new experimental data, which helps improve the AI system over time.

This process is often called a “closed-loop” AI system because the AI constantly learns from new results and improves itself.

A Growing Trend in AI Biotech

AI-powered biotech has become one of the fastest-growing sectors in technology during 2026.

Companies are increasingly using artificial intelligence to accelerate scientific research, especially in healthcare and drug discovery.

Imperagen joins a growing group of startups using AI for enzyme engineering, including Biomatter, Cradle Bio, and Absci.

New CEO to Lead Expansion

Alongside the funding announcement, Imperagen also introduced Guy Levy-Yurista as its new CEO.

He brings experience in artificial intelligence, enterprise technology, and life sciences. According to the company, his role will focus on scaling Imperagen’s AI infrastructure and building more industrial partnerships.

The startup plans to use the new funding to:

• Hire additional AI specialists
• Expand research and development
• Improve laboratory capabilities
• Build commercial partnerships
• Scale its AI-driven enzyme platform

Why This Matters

The combination of AI, automation, and biotechnology could dramatically speed up scientific innovation over the next few years.

If companies like Imperagen succeed, industries may be able to create cleaner, safer, and more sustainable products faster than before.

The company believes engineered enzymes could eventually help reduce industrial waste, improve manufacturing efficiency, and support more environmentally friendly production methods.

As AI continues expanding into healthcare and biotechnology, startups like Imperagen are showing how advanced technologies may reshape scientific research in the future.